In the phase 2 NURTURE study (Table 1), nusinersen was given to infants who were presymptomatic and had a genetically confirmed diagnosis of SMA with 2 or 3 copies of SMN2 [3] (p. 2). The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.